Thyroid News and Research

RSS

Neonatal TSH screening insensitive for iodine insufficiency

Measuring levels of neonatal thyroid-stimulating hormone may not be sufficiently sensitive for inferring the extent of iodine deficiency in a given population, study results suggest.

5 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Multiple sclerosis disease activity reduced by leukaemia drug, even when first-line treatment has failed

A drug which was originally developed to treat leukaemia and other cancers of the immune system offers substantial improvements over existing treatments in reducing relapse rates for people with multiple sclerosis (MS), even when they have not responded well to first-line treatment, according to the results of two phase 3 trials published Online First in The Lancet.

1 Nov 2012

Hospice volunteers' satisfaction relies on appreciation, support

The majority of individuals involved with nine Canadian hospice volunteer programs are satisfied with their work, citing the appreciation and gratitude of patients and their families as the most satisfying aspect of volunteering, indicate study results.

31 Oct 2012

Pediatric hospitalists keen on texting, worry about privacy

An overwhelming majority of pediatric hospitalists use a smartphone and text messaging, while approximately half either send or receive work-related text messages while they are on duty, show survey findings.

30 Oct 2012

Universal approach to MRSA-prevention in ICU is most effective

Universal decolonization of all patients admitted to intensive care units using chlorhexidine baths and mupirocin treatment for 5 days significantly reduces the risk for infection with methicillin-resistant Staphylococcus aureus , report researchers.

26 Oct 2012

Removing rotavirus vaccine age restrictions could save lives

Removing or relaxing the current rotavirus vaccine age restrictions would help save children’s lives, especially in low- and middle-income countries, say researchers.

25 Oct 2012

Study indicates that Firemaster 550 is an endocrine disruptor

The flame-retardant mixture known as "Firemaster 550" is an endocrine disruptor that causes extreme weight gain, early onset of puberty and cardiovascular health effects in lab animals, according to a new study spearheaded by researchers from North Carolina State University and Duke University.

25 Oct 2012

Medical students want more ethics training

Almost two-thirds of medical students and residents feel that there is a need for more ethics training during their curricula and training programs, respectively, show results of a survey undertaken at a US medical school.

23 Oct 2012

Almost all children on intensive care units given ‘off-label’ drugs

Study results show that a very high proportion of children admitted to intensive care units are treated with “off-label” drugs that have not been tested for the specific age or condition of the patient.

23 Oct 2012

Genzyme, Alnylam partner to develop and commercialize RNAi therapeutics against ATTR

Alnylam Pharmaceuticals, Inc. and Genzyme, a Sanofi company, announced today that they have formed an exclusive alliance to develop and commercialize RNAi therapeutics targeting transthyretin (TTR) for the treatment of transthyretin-mediated amyloidosis (ATTR) in Japan and other Asia-Pacific countries.

23 Oct 2012

Quality of care drops if doctors dictate

Physicians who predominantly dictate patients’ medical notes have worse quality of care than their peers who use structured electronic health record documentation, show study findings.

19 Oct 2012

Phase 3 study of INLYTA fails to meet primary endpoint in treatment-naïve patients with RCC

Pfizer Inc. announced today that a Phase 3 study of INLYTA (axitinib) did not meet its primary endpoint of demonstrating statistically significantly longer progression-free survival, versus sorafenib, in treatment-naïve patients with advanced renal cell carcinoma.

18 Oct 2012